Update to living WHO guideline on drugs for covid-19

  title={Update to living WHO guideline on drugs for covid-19},
  • anonymous
  • Published 19 November 2020
  • Medicine
  • BMJ

Emergence of SARS‐CoV‐2 Omicron variant and strategies for tackling the infection

A systematic database search summarizes the salient features of Omicron sublineages, and their impact on transmissibility, disease severity as well as the efficacy of the available vaccines and treatment against the OmicRON.

What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic

I should highlight that this manuscript is not a formal review on the topic, but a report from an ESOT meeting held on 22 June 2022. The assumption of immunosuppressants exposes kidney transplant

Respiratory viruses: their importance and lessons learned from COVID-19.

The epidemiology, diagnosis, clinical characteristics, management and prognosis of patients with severe infections due to respiratory viruses, and biomarkers are discussed.

In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

When to Use Antibiotics in COVID-19: A Proposal Based on Questions

There is no evidence to justify the systematic use of antimicrobials in COVID-19, and the recommendations seek to provide knowledge regarding treatment.

Procalcitonin as a Predictive Factor for the Clinical Outcome of Patients with Coronavirus Disease 2019

Measurement of procalcitonin and other biomarkers may be useful to determine whether to use or discontinue use of antibacterial drugs in patients with COVID-19.

Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice

Head-to-head clinical trials are critically important to advance the field of IBD and alternative approaches to comparative effectiveness such as network meta-analysis and well designed real-world observational studies are able to bridge gaps in clinical practice.

Multiple Sclerosis Management During the COVID-19 Pandemic

The goal is to provide an overarching review of the major findings at this stage of the pandemic relevant to those that care for patients with MS, and to explore potential ways in which a COVID-19 infection may impact multiple sclerosis.

Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences

The similarities and differences in the pathogenesis, pathophysiology, clinical features and treatment strategies of COVID-19 induced acute respiratory failure and typical ARDS are discussed.